Why did IOBT stock spike in volume today?

IOBT stock volume jumped after IO Biotech announced it would explore strategic alternatives, including a potential sale, merger, or liquidation. That Jan 21, 2026 news increased trading and speculative interest, producing heavy intraday and after-hours volume.

What is Meyka AI’s grade for IOBT stock?

Meyka AI rates IOBT with a score out of 100 at **62.14**, graded **B** with a **HOLD** suggestion. The grade considers benchmarks, sector performance, financial growth, key metrics, and analyst views.

What does Meyka AI forecast for IOBT stock?

Meyka AI's forecast model projects a one-year price of **$0.5023**, implying about **+7.72%** upside from **$0.4663**. Forecasts are model-based projections and not guarantees; markets can move differently.

Is IOBT stock a buy after the strategic alternatives announcement?

The announcement creates short-term trading opportunities but raises material risk. Consider high volatility, negative EPS, and possible dilution. IOBT stock may suit speculative traders, not conservative investors.

US Stocks

IOBT IO Biotech, Inc. (NASDAQ) $0.47 on 22 Jan 2026: active intraday mover for traders

ByDanny Kontos January 23, 2026January 23, 2026

IOBT stock traded at $0.4663 intraday on 22 Jan 2026 after IO Biotech announced a review of strategic alternatives. The move sent volume to 388,808,343 shares versus an average of 1,027,588, making IOBT one of the most active Nasdaq tickers in the United States today. Traders are pricing in outcomes from asset sales to a possible merger, and the stock’s swing continues to outpace the biotech sector.